Clinical Trials Logo
  1. Home
  2. Metastatic Uveal Melanoma
  3. NCT01551459

A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma — SUAVE  

Metastatic Uveal Melanoma Clinical Trial

Official title:
A Randomised Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma

Clinical Trial Summary

Doctors usually treat uveal melanoma with radiotherapy or surgery. But if this cancer spreads, it is more difficult to treat.

Doctors usually treat uveal melanoma that has spread with a chemotherapy called dacarbazine, but they are always looking to find new ways to treat uveal melanoma.

This study aims to find out how well Sunitinib works to treat uveal melanoma and to see how long Sunitinib and Dacarbazine can help to prevent the cancer from getting worse.

Clinical Trial Description

124 eligible patients will be randomised to either Sunitinib or Dacarbazine treatment. Participants will then attend 3-weekly clinic visits and undergo 12-weekly tumour assessment (CT or MRI scan) until disease progression (according to RECIST 1.1) has been identified.

At progression, patients may crossover to the other study treatment and continue with 3-weekly clinic visits and 12-weekly imaging until second progression. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01551459
Study type Interventional
Source The Clatterbridge Cancer Centre NHS Foundation Trust
Contact
Status Completed
Phase Phase 2
Start date October 2010
Completion date November 2017
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03068624 - Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma Phase 1
Recruiting NCT04728633 - Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases Phase 2
Recruiting NCT05987332 - IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Phase 2/Phase 3
Recruiting NCT06121180 - Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma Phase 2
Active, not recruiting NCT00986661 - A Study to Assess PV-10 Chemoablation of Cancer of the Liver Phase 1
Active, not recruiting NCT01585194 - Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma Phase 2
Withdrawn NCT01328106 - Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma Phase 2
Recruiting NCT05075993 - Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors Phase 1
Active, not recruiting NCT04552223 - Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma Phase 2
Recruiting NCT05607095 - Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma Phase 1
Active, not recruiting NCT03472586 - Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver Phase 2
Active, not recruiting NCT03025256 - Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease Phase 1
Active, not recruiting NCT04879017 - FHD-286 in Subjects With Metastatic Uveal Melanoma Phase 1
Terminated NCT01814046 - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma Phase 2
Recruiting NCT03947385 - Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Phase 1/Phase 2
Active, not recruiting NCT03865212 - Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma Phase 1
Active, not recruiting NCT05022901 - An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma Phase 3
Recruiting NCT05282901 - Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) Phase 2
Recruiting NCT05415072 - A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas Phase 1/Phase 2
Active, not recruiting NCT04720417 - Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma Phase 2